First-in-Human Single and Multiple Dose of HL-400

Summary

This is a randomized, double-blind, placebo-controlled, dose-escalation study in healthy subjects to evaluate the safety, tolerability, pharmacokinetics of HL-400 (a NLRP3 inhibitor) following oral single and multiple ascending dose administration.

Timeline

Start

2025-04-25

Primary completion

2026-06-30

Completion

2026-10-27

Drugs

Indications